文献速递腹部MR

治疗前3.0 T MRI肝胆期边缘强化:XELOX化疗后结直肠癌肝转移早期化疗反应的潜在标志物

Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX.
PubMed 文献 · Eur J Radiol · 2021-08-13

本研究回顾性纳入65例结直肠癌肝转移患者,治疗前接受Gd-EOB-DTPA增强MRI,评估肝胆期最大病灶的强化模式及信号强度比值与化疗反应的关系。结果显示,肝胆期边缘强化在反应组更常见(72% vs 31%),肝胆期强化模式和SIcenter/outer是化疗反应的独立因素,联合参数AUC达0.821。

要点

  • 治疗前肝胆期边缘强化提示结直肠癌肝转移对XELOX化疗更可能反应。
  • 肝胆期强化模式与SIcenter/outer是化疗反应的独立预测因素。
  • 联合直径、强化模式及信号强度比值可提高预测化疗反应的AUC至0.821。

关键影像表现/征象

  • 肝胆期边缘强化在化疗反应组28例中占72%,在非反应组8例中占31%。
  • 化疗反应与病灶直径(P=0.04)、SIcenter/outer(P=0.047)及SIrim/center(P=0.012)显著相关。
  • 肝胆期对比增强模式(P=0.007)和SIcenter/outer(P=0.022)是化疗反应的独立因素。

诊断标准与关键数值

  • 直径预测化疗反应的AUC为0.638。
  • 肝胆期对比增强模式预测化疗反应的AUC为0.706。
  • SIcenter/outer预测化疗反应的AUC为0.712。
  • SIrim/center预测化疗反应的AUC为0.673。
  • 上述参数联合预测化疗反应的AUC最大,为0.821。

临床应用与阅片要点

  • 阅片时可关注结直肠癌肝转移病灶在肝胆期的边缘强化表现,作为化疗反应的潜在预测指标。
  • 可测量并计算肝胆期病灶的信号强度比值(SIcenter/outer、SIrim/center),辅助评估化疗反应可能性。
  • 联合病灶直径、肝胆期强化模式及信号强度比值参数,可提高预测化疗反应的效能。

局限性

  • 本研究为单中心回顾性研究,样本量有限(65例),结论需进一步前瞻性验证。
  • 肝转移诊断基于影像学表现,未全部经病理证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the value of the enhanced features on the hepatobiliary phase (HBP) of pre-treatment Gd-EOB-DTPA MRI in evaluating response to chemotherapy in colorectal liver metastases (CRLMs).

METHODS: We retrospectively studied 65 patients with CRLMs who underwent Gd-EOB-DTPA enhanced MRI before chemotherapy from October 2015 to November 2017. The diagnosis of liver metastasis was established on the basis of imaging findings. Two radiologists evaluated the size, contrast-enhanced (CE) patterns of the maximum lesion on the HBP. According to the different CE patterns, we quantified area signal intensity (SI) by applying SI ratio (such as SIcenter/outer and SIrim/center). All of the above parameters were analyzed in terms of chemotherapy response.

RESULTS: Rim enhancement on the HBP was more frequent in the responding group of 28 patients (72%) than in the non-responding group of eight patients (31%). Additionally, there was a significant association between chemotherapy response and quantitative parameters: including diameter (P = 0.04), SIcenter/outer (P = 0.047) and SIrim/center (P = 0.012). The HBP CE pattern (P = 0.007) and SIcenter/outer (P = 0.022) were independent factors for chemotherapy response. The areas under the curve (AUCs) of the above-mentioned parameters were significant associated with response to chemotherapy, in which diameter, HBP CE patterns, SIcenter/outer, and SIrim/center were 0.638, 0.706, 0.712, and 0.673, respectively. Moreover, the combination of these parameters obtained the largest AUC of 0.821.

CONCLUSION: The CE patterns, in particular with rim enhancement, and SI ratio parameters on the HBP are useful indicators for early evaluation of therapeutic response after chemotherapy in patients with CRLMs.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang X, Wang Y, Zhang Z, et al. Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX. Eur J Radiol. 2021. PMID: 34454297. doi:10.1016/j.ejrad.2021.109887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。